日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING study

托法替尼减量治疗稳定缓解期溃疡性结肠炎患者疗效结果的潜在预测因素:RIVETING 研究结果的事后分析

Torres, Joana; D'Haens, Geert R; Regueiro, Miguel; Santana, Genoile; Panés, Julian; Vermeire, Séverine; Gardiner, Sean; Kulisek, Nicole; Modesto, Irene; Su, Chinyu; Lawendy, Nervin; Mundayat, Rajiv; Paulissen, Jerome; Dubinsky, Marla C

Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure

对已完成的全球临床开发项目中托法替尼治疗溃疡性结肠炎的安全性进行分析,药物暴露时间长达 9.2 年。

Panés, Julian; D'Haens, Geert R; Sands, Bruce E; Ng, Siew C; Lawendy, Nervin; Kulisek, Nicole; Guo, Xiang; Wu, Joseph; Vranic, Ivana; Panaccione, Remo; Vermeire, Séverine

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme

托法替尼治疗溃疡性结肠炎:全球临床项目长达 7.8 年安全性数据的综合总结

Sandborn, William J; D'Haens, Geert R; Sands, Bruce E; Panaccione, Remo; Ng, Siew C; Lawendy, Nervin; Kulisek, Nicole; Modesto, Irene; Guo, Xiang; Mundayat, Rajiv; Su, Chinyu; Vranic, Ivana; Panés, Julian

Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore

托法替尼作为溃疡性结肠炎患者的维持治疗,根据 OCTAVE Sustain 基线 Mayo 内镜亚评分进行分层。

Lee, Scott D; Allegretti, Jessica R; Steinwurz, Flavio; Connelly, Susan B; Lawendy, Nervin; Paulissen, Jerome; Gecse, Krisztina B

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

托法替尼治疗溃疡性结肠炎:溃疡性结肠炎临床项目的感染率分析

Winthrop, Kevin L; Loftus, Edward V; Baumgart, Daniel C; Reinisch, Walter; Nduaka, Chudy I; Lawendy, Nervin; Chan, Gary; Mundayat, Rajiv; Friedman, Gary S; Salese, Leonardo; Thorpe, Andrew J; Su, Chinyu

Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial

来自随机 RIVETING 试验的托法替尼剂量减少对处于稳定缓解期的溃疡性结肠炎患者的影响

Vermeire, Séverine; Su, Chinyu; Lawendy, Nervin; Kobayashi, Taku; Sandborn, William J; Rubin, David T; Modesto, Irene; Gardiner, Sean; Kulisek, Nicole; Zhang, Haiying; Wang, Wenjin; Panés, Julian

Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials

托法替尼治疗溃疡性结肠炎中断后再次治疗的疗效和安全性:OCTAVE临床试验结果

Panés, Julian; Vermeire, Séverine; Dubinsky, Marla C; Loftus, Edward V; Lawendy, Nervin; Wang, Wenjin; Salese, Leonardo; Su, Chinyu; Modesto, Irene; Guo, Xiang; Colombel, Jean-Frederic

The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme

体重指数对托法替尼OCTAVE溃疡性结肠炎临床项目的疗效和安全性的影响

Farraye, Francis A; Qazi, Taha; Kotze, Paulo G; Moore, Gregory T; Mundayat, Rajiv; Lawendy, Nervin; Sharma, Puza P; Judd, Donna T

Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program

托法替尼,一种口服 Janus 激酶抑制剂:溃疡性结肠炎临床项目中恶性肿瘤(不包括非黑色素瘤皮肤癌)事件的分析

Lichtenstein, Gary R; Rogler, Gerhard; Ciorba, Matthew A; Su, Chinyu; Chan, Gary; Pedersen, Ronald D; Lawendy, Nervin; Quirk, Daniel; Nduaka, Chudy I; Thorpe, Andrew J; Panés, Julian